Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: Clinical and biological activity

Clinical Breast Cancer

Volumn 12, Issue 3, 2012, Pages 207-214

  Montagna, Emilia ^a   Cancello, Giuseppe ^a   Bagnardi, Vincenzo ^a,b   Pastrello, Davide ^a   Dellapasqua, Silvia ^a   Perri, Gino ^a   Viale, Giuseppe ^a,c   Veronesi, Paolo ^a,c   Luini, Alberto ^a   Intra, Mattia ^a   Calleri, Angelica ^a   Rampinelli, Cristiano ^a   Goldhirsch, Aron ^a   Bertolini, Francesco ^a   Colleoni, Marco ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Bevacizumab; Erlotinib; Metronomic chemotherapy

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; ADVANCED CANCER; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; ASTHENIA; BIOLOGICAL ACTIVITY; BLEEDING; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVOR; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONSTIPATION; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DISEASE COURSE; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; DYSGEUSIA; ENDOTHELIAL PROGENITOR CELL; FEMALE; FEVER; FOLLICULITIS; HAND FOOT SYNDROME; HEMATURIA; HOT FLUSH; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; INFECTION; KERATITIS; LEUKOPENIA; LIVER METASTASIS; LOCAL SKIN REACTION; LUNG METASTASIS; LYMPH NODE METASTASIS; METRONOMIC DRUG ADMINISTRATION; MUCOSA INFLAMMATION; NAUSEA; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PAIN; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SOFT TISSUE METASTASIS; STOMACH PAIN; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; VOMITING;

EID: 84861111904     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2012.03.008     Document Type: Article

References (29)

1. M. Colleoni, A. Rocca, M.T. Sandri Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels Ann Oncol 13 2002 73 80
2. J. Lokich Capecitabine: fixed daily dose and continuous (noncyclic) dosing schedule Cancer Invest 22 2004 713 717
3. H.J. Burstein, D. Spigel, K. Kindsvogel Metronomic chemotherapy with and without bevacizumab for advanced breast cancer: A randomized phase II study Paper presented at: 28th Annual San Antonio Breast Cancer Symposium December 8-11, 2005 San Antonio, TX. Abstact 4
4. K.J. Kim, B. Li, J. Winer Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo Nature 1993 1993 841 844
5. K. Miller, M. Wang, J. Gralow Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer N Engl J Med 357 2007 2666 2676
6. S. Dellapasqua, F. Bertolini, V. Bagnardi Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer J Clin Oncol 26 2008 4899 4905
7. A. Hirata, S. Ogawa, T. Kometani ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase Cancer Res 62 2002 2554 2560
8. A. Bozec, J.L. Fischel, G. Milano Epidermal growth factor receptor/angiogenesis dual targeting: preclinical experience Curr Opin Oncol 18 2006 330 334
9. J.G. Klijn, M.P. Look, H. Portengen The prognostic value of epidermal growth factor receptor (EGF-R) in primary breast cancer: results of a 10 year follow-up study Breast Cancer Res Treat 29 1994 73 83
10. S. Tsutsui, S. Ohno, S. Murakami Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer Breast Cancer Res Treat 71 2002 67 75
11. V. Pawlowski, F. Révillion, M. Hebbar Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay Clin Cancer Res 6 2000 4217 4225
12. M.T. Sandri, H.A. Johansson, L. Zorzino Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in patients with metastatic breast cancer treated with metronomic chemotherapy Cancer 110 2007 509 517
13. R.S. Herbst, D.H. Johnson, E. Mininberg Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer J Clin Oncol 23 2005 2544 2555
14. M.N. Dickler, H.S. Rugo, C.A. Eberle A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer Clin Cancer Res 14 2008 7878 7883
15. P. Therasse, S.G. Arbuck, E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors European Organization for Research and Treatment of Cancer: National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
16. P. Mancuso, P. Antoniotti, J. Quarna Validation of a standardized method for enumerating circulating endothelial cells and progenitors: flow cytometry and molecular and ultrastructural analyses Clin Cancer Res 15 2009 267 273
17. A. Calleri, A. Bono, V. Bagnardi Predictive potential of angiogenic growth factors and circulating endothelial cells in breast cancer patients receiving metronomic chemotherapy plus bevacizumab Clin Cancer Res 15 2009 7652 7657
18. N.J. Robert, V. Diéras, J. Glaspy RIBBON-1: Randomized, double-blind placebo controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer J Clin Oncol 29 2011 1252 1260
19. A.M. Brufsky, S. Hurvitz, E. Perez Ribbon-2: A randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer J Clin Oncol 10 2011 4286 4293
20. S. Modi, G. D'Andrea, L. Norton A phase I study of cetuximab/paclitaxel in patients with advanced-stage breast cancer Clin Breast Cancer 7 2006 270 277
21. K. Albain, R. Elledge, W. Gradishar Open-label phase II, multicenter trial of ZD 1839 (Iressa) in patients with advanced breast cancer Breast Cancer Res Treat 76 2002 A20
22. M.N. Dickler, M.A. Cobleigh, K.D. Miller Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer Breast Cancer Res Treat 115 2009 115 121
23. A. Bozec, J.L. Fischel, G. Milano Epidermal growth factor receptor/angiogenesis dual targeting: preclinical experience Curr Opin Oncol 18 2006 330 334
24. F. Ciardiello, R. Bianco, V. Damiano Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells Clin Cancer Res 6 2000 3739 3747
25. A. Viloria-Petit, T. Crombet, S. Jothy Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis Cancer Res 61 2001 5090 5101
26. M.N. Dickler, H.S. Rugo, C.A. Eberle A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer Clin Cancer Res 14 2008 7878 7883
27. R.S. Kerbel Tumor angiogenesis N Engl J Med 358 2008 2039 2049
28. F. Bertolini, P. Marighetti, Y. Shaked Cellular and soluble markers of tumor angiogenesis: from patient selection to the identification of the most appropriate post resistance therapy Biochim Biophys Acta 180 2010 131 137
29. I. Smith, J.Y. Pierga, L. Biganzoli Final overall survival results and effect of prolonged (< 1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial Breast Cancer Res Treat 130 2011 133 143